Novartis | Company & Product Resources
ALL-IN-ONE Relief of COSENTYX®
​
This handout highlights COSENTYX® as an all-in-one treatment option for patients with psoriatic arthritis (PsA), focusing on results across key clinical manifestations. It also reinforces the availability of both SC and IV formulations, providing options for patients to start and stay on COSENTYX.
Click Image Below
Your Impact Deserves a Round of APP-lause!​
​
This handout recognizes and thanks APPs for their longstanding partnership in helping bring COSENTYX® to patients. It highlights the impact of APPs and directs them to additional SC and IV resources and educational materials.
Click Image Below
Get Patients Started on the IV Formulation of COSENTYX®â€‹
​
This handout provides healthcare professionals with a comprehensive guide to the IV formulation of COSENTYX® (secukinumab). It includes key information on dosing, administration, and billing, along with an overview of the IV formulation and its approved indications.
Click Image Below
Treatment Guidelines Support the Use of IL-17 Inhibitors, Such as COSENTYX®, as a First-Line Biologic in PsA
​
This handout summarizes EULAR and GRAPPA treatment guidelines for psoriatic arthritis (PsA), highlighting recommendations supporting IL-17 inhibitors, such as COSENTYX®, as a first-line biologic treatment option. It also reinforces COSENTYX results across all key clinical manifestations of PsA.
Click Image Below
The ESSDAI Explained: Assessing Sjögren's Disease Activity
​
Explore the role of the ESSDAI in assessing the disease activity of Sjögren's disease and review clinical insights from Audrey Gibson, PA-C, MSPAS, CCD.
Click Image Below
Tracking Disease Activity and Progression in Sjögren’s Disease
Click Image Below
Expert Exchange on Sjögren’s Disease: An Autoimmune Disease That Can Be Serious and Progressive
​
Sjögren’s disease is more than dryness, often featuring sicca symptoms. Join Teja Kapoor, MD, Adam Doré, DO, and Erin Siceloff, PA, as they explore the systemic and heterogeneous nature of this serious disease.
Expert Exchange on Sjögren’s Disease: Uncovering Systemic Disease Burden Through ESSDAI Domains
​
Discover how ESSDAI-based questions help reveal systemic involvement in Sjögren’s disease. Teja Kapoor, MD, and Adam Doré, DO, highlight key domains, including glandular, articular, cutaneous, and lymphadenopathy.
Expert Exchange on Sjögren’s Disease: Identifying Your Patients Who Are "Sicca Plus" May Help Enable Timely, Targeted Intervention With Biologic Therapy
​
Learn how the “sicca plus” framework can help identify patients with Sjögren’s disease who may be eligible for biologic therapy. Teja Kapoor, MD, Adam Doré, DO, and Erin Siceloff, PA, illustrate its use through patient cases.
Expert Exchange on Sjögren’s Disease: A B-Cell–Driven Disease With Inadequate Treatment Options
​​
Teja Kapoor, MD, and Adam Doré, DO, explore the underlying pathogenesis of Sjögren’s disease, including the critical role of B cells, and discuss unmet treatment needs.